Abvc Biopharma (ABVC) Long-Term Debt Repayments (2019 - 2024)
Abvc Biopharma's (ABVC) quarterly Long-Term Debt Repayments came in at $147892.0 in Q4 2024, down 85.21% on a QoQ basis from $1.0 million in Q1 2023.
Abvc Biopharma (ABVC) Long-Term Debt Repayments (2019 - 2024) Analysis & Trends
Abvc Biopharma (ABVC) has 5 years of Long-Term Debt Repayments data on file, last reported at $147892.0 in Q4 2024.
- Quarterly Long-Term Debt Repayments changed N/A year-over-year to $147892.0 in Q4 2024, while the trailing twelve-month figure through Dec 2025 was $1.1 million (changed 0.0% YoY) and the FY2025 annual result came in at $277284.0, down 15.21% from the prior year.
- Long-Term Debt Repayments fell to $147892.0 in Q4 2024, from $1.0 million in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $1.0 million in Q1 2023 to a low of $121.0 in Q3 2020.
- A 4-year average of $245458.7 and a median of $147892.0 in 2024 frame the typical range for Long-Term Debt Repayments.
- The widest YoY moves for Long-Term Debt Repayments: up 2716.28% in 2020, down 99.05% in 2020.
- Tracing ABVC's Long-Term Debt Repayments over 4 years: stood at $121.0 in 2020, then soared by 46871.9% to $56836.0 in 2021, then surged by 1659.45% to $1.0 million in 2023, then tumbled by 85.21% to $147892.0 in 2024.
- The last three Long-Term Debt Repayments figures came in at $147892.0 (Q4 2024), $1.0 million (Q1 2023), and $56836.0 (Q2 2021), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -10.01 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 147,892.00 |
| Dec 31, 2024 | 147,892.00 |
| Mar 31, 2023 | 1.00 Mn |
| Mar 31, 2023 | 1.00 Mn |
| Jun 30, 2021 | 56,836.00 |
| Jun 30, 2021 | 56,836.00 |
| Mar 31, 2021 | 250,000.00 |
| Mar 31, 2021 | 250,000.00 |
| Sep 30, 2020 | 121.00 |
| Sep 30, 2020 | 121.00 |
| Jun 30, 2020 | 253,381.00 |
| Jun 30, 2020 | 253,381.00 |
| Mar 31, 2020 | 9,981.00 |
| Mar 31, 2020 | 9,981.00 |
| Dec 31, 2019 | 9,883.00 |
| Dec 31, 2019 | 9,883.00 |
| Sep 30, 2019 | 12,690.00 |
| Sep 30, 2019 | 12,690.00 |
| Jun 30, 2019 | 8,997.00 |
| Jun 30, 2019 | 8,997.00 |